Search
19 hours ago
BIO-Europe: The CEO of Sweden's Affibody on trying to be better than antibodies, moving into the radiopharmaceutical space, and IPO rumors
David Bejker describes how affibody's are meant to compete with monoclonal antibodies, which the company's lead program in IL-17. Plus,...